Full Text Journal Articles by
Author Corine Chazallon

Advertisement

Find full text journal articles








Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.

Irja Lutsar, Corine Chazallon, Ursula Trafojer, Vincent Meiffredy de Cabre, Cinzia Auriti, Chiara Bertaina, Francesca Ippolita Calo Carducci, Fuat Emre Canpolat, Susanna Esposito, Isabelle Fournier, Maarja Hallik, Paul T Heath, Mari-Liis Ilmoja, Elias Iosifidis, Jelena Kuznetsova, Laurence Meyer, Tuuli Metsvaht, George Mitsiakos, Zoi Dorothea Pana, Fabio Mosca, Lorenza Pugni, Emmanuel Roilides, Paolo Rossi, Kosmas Sarafidis, Laura Sanchez, Michael Sharland, Vytautas Usonis, Adilia Warris, Jean-Pierre Aboulker, Carlo Giaquinto, ,

BACKGROUND:The early use of broad-spectrum antibiotics remains the cornerstone for the treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still debatable, as relevant studies were conducted more than 20 years ago, recruited in single centres or countries, evaluated antibiotics not in clinical use anymore ... Read more >>

PLoS ONE (PloS one)
[2020, 15(3):e0229380]

Cited: 0 times

View full text PDF listing >>



Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial

Irja Lutsar, Corine Chazallon, Ursula Trafojer, Vincent Meiffredy de Cabre, Cinzia Auriti, Chiara Bertaina, Francesca Ippolita Calo Carducci, Fuat Emre Canpolat, Susanna Esposito, Isabelle Fournier, Maarja Hallik, Paul Heath Frcpch, Mari-Liis Ilmoja, Elias Iosifidis, Jelena Kuznetsova, Laurence Meyer, Tuuli Metsvaht, George Mitsiakos, Zoi Dorothea Pana, Fabio Mosca, Lorenza Pugni, Emmanuel Roilides, Paolo Rossi, Kosmas Sarafidis, Laura Sanchez, Michael Sharland, Vytautas Usonis, Adilia Warris, Jean-Pierre Aboulker, Carlo Giaquinto, ,

Abstract Background The early use of broad-spectrum antibiotics remains the cornerstone for the treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still debatable, as relevant studies were conducted more than 20 years ago, were single centre or country, insufficiently powered, evaluated antibiotics not in ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.

Eva Germovsek, Irja Lutsar, Karin Kipper, Mats O Karlsson, Tim Planche, Corine Chazallon, Laurence Meyer, Ursula M T Trafojer, Tuuli Metsvaht, Isabelle Fournier, Mike Sharland, Paul Heath, Joseph F Standing, ,

Background:Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking. Objectives:To ... Read more >>

J. Antimicrob. Chemother. (The Journal of antimicrobial chemotherapy)
[2018, 73(7):1908-1916]

Cited: 1 time

View full text PDF listing >>



Current management of late onset neonatal bacterial sepsis in five European countries.

Irja Lutsar, Corine Chazallon, Francesca Ippolita Calò Carducci, Ursula Trafojer, Ben Abdelkader, Vincent Meiffredy de Cabre, Susanna Esposito, Carlo Giaquinto, Paul T Heath, Mari-Liis Ilmoja, Aspasia Katragkou, Carine Lascoux, Tuuli Metsvaht, George Mitsiakos, Emmanuelle Netzer, Lorenza Pugni, Emmanuel Roilides, Yacine Saidi, Kosmas Sarafidis, Mike Sharland, Vytautas Usonis, Jean-Pierre Aboulker, ,

Late onset neonatal sepsis (LOS) has a high mortality and the optimal management is poorly defined. We aimed to evaluate new expert panel-derived criteria to define LOS and characterize the current management and antibiotic susceptibility of LOS-causing organisms in Europe. A prospective observational study enrolled infants aged 4 to 90 days ... Read more >>

Eur. J. Pediatr. (European journal of pediatrics)
[2014, 173(8):997-1004]

Cited: 15 times

View full text PDF listing >>



Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.

Lucile Larrouy, Charlotte Charpentier, Roland Landman, Catherine Capitant, Corine Chazallon, Patrick Yeni, Gilles Peytavin, Florence Damond, Françoise Brun-Vezinet, Diane Descamps, ,

OBJECTIVE: Recently, we have reported the role of baseline gag cleavage site mutations on the virological outcome of a dual-boosted protease inhibitor regimen in antiretroviral-naive patients (2IP-ANRS 127 trial). The objective of this substudy was to characterize, in patients experiencing virological failure, from the 2IP-ANRS 127 trial, the viral quasispecies ... Read more >>

AIDS (AIDS (London, England))
[2011, 25(17):2143-2148]

Cited: 2 times

View full text PDF listing >>



Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.

Vassilis Tsatsaris, Catherine Capitant, Thomas Schmitz, Corine Chazallon, Sophie Bulifon, Didier Riethmuller, Olivier Picone, Patrice Poulain, Fanny Lewin, Fabrice Lainé, Evelyne Jacqz-Aigrain, Jean-Pierre Aboulker, Odile Launay, ,

BACKGROUND: Pregnant women and infants who get influenza are at increased risk for severe illness. OBJECTIVE: To evaluate the immunogenicity and transplacental antibody transfer of 2009 pandemic influenza A(H1N1) vaccine administered during pregnancy. DESIGN: Prospective, multicenter, single-group clinical trial. (ClinicalTrials.gov registration number: NCT01024400) SETTING: Five level-3 perinatal centers in France. ... Read more >>

Ann. Intern. Med. (Annals of internal medicine)
[2011, 155(11):733-741]

Cited: 36 times

View full text PDF listing >>



Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.

Diane Descamps, Corine Chazallon, Clive Loveday, Lee Bacheler, Ruth Goodall, Patrick Yéni, David A Cooper, Abdel Babiker, Jean-Pierre Aboulker, Francoise Brun-Vézinet, ,

PURPOSE: To study the impact of baseline resistance mutations and HIV-1 subtypes on virological response to first-line antiretroviral therapy and to analyse the concordance of the results of two antiretroviral resistance interpretation tools in the INITIO trial. METHOD: Genotype and virco TYPE resistance analyses were studied at baseline, Year 2, ... Read more >>

HIV Clin Trials (HIV clinical trials)
[2009, 10(6):385-393]

Cited: 1 time

View full text PDF listing >>



Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Roland Landman, Catherine Capitant, Diane Descamps, Corine Chazallon, Gilles Peytavin, Christine Katlama, Gilles Pialoux, Michelle Bentata, Francoise Brun-Vézinet, Jean-Pierre Aboulker, Patrick Yéni, ,

OBJECTIVES: We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients. METHODS: Thirty patients received fosamprenavir/atazanavir/ritonavir (Group 1) and 31 patients received saquinavir/atazanavir/ritonavir (Group 2). The primary endpoint for efficacy was the ... Read more >>

J. Antimicrob. Chemother. (The Journal of antimicrobial chemotherapy)
[2009, 64(1):118-125]

Cited: 7 times

View full text PDF listing >>



External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.

Anne-Geneviève Marcelin, Corine Chazallon, Laurence Gérard, Yacine Saïdi, Jean-Pierre Aboulker, Pierre-Marie Girard, Vincent Calvez, Christophe Piketty,

J. Acquir. Immune Defic. Syndr. (Journal of acquired immune deficiency syndromes (1999))
[2006, 42(1):127-128]

Cited: 4 times

View full text PDF listing >>



Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

Laurence Gérard, Corine Chazallon, Anne-Marie Taburet, Pierre-Marie Girard, Jean-Pierre Aboulker, Christophe Piketty,

OBJECTIVE: To determine the evolution of renal function in highly treatment-experienced patients with normal renal function at baseline receiving tenofovir disoproxil fumarate (TDF) as part of a fixed combined antiretroviral regimen and to identify prognostic factors of change in renal function, including tenofovir concentrations. METHODS: A prospective 48-week open-label trial ... Read more >>

Antivir. Ther. (Lond.) (Antiviral therapy)
[2007, 12(1):31-39]

Cited: 15 times

View full text PDF listing >>



Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Christophe Piketty, Laurence Gérard, Corine Chazallon, Anne-Geneviève Marcelin, François Clavel, Anne-Marie Taburet, Vincent Calvez, Isabelle Madelaine-Chambrin, Jean-Michel Molina, Jean-Pierre Aboulker, Pierre-Marie Girard, ,

BACKGROUND: Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties. METHODS: A 26-week study of the safety and efficacy of RTV-boosted ATV plus TDF-DF was conducted in 53 HIV-infected patients who were failing their ... Read more >>

Antivir. Ther. (Lond.) (Antiviral therapy)
[2006, 11(2):213-221]

Cited: 5 times

View full text PDF listing >>



Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures.

Christophe Piketty, Laurence Gérard, Corine Chazallon, Vincent Calvez, François Clavel, Anne-Marie Taburet, Pierre-Marie Girard, Jean-Pierre Aboulker, ,

No significant changes in viral load and CD4 cell count were observed 2-4 weeks after the withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTI) from the current therapy of patients exhibiting resistance mutations to this class of drugs. The data suggest that in the presence of specific resistance mutations NNRTIexert no ... Read more >>

AIDS (AIDS (London, England))
[2004, 18(10):1469-1471]

Cited: 3 times

View full text PDF listing >>



Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.

Anne-Marie Taburet, Christophe Piketty, Corine Chazallon, Isabelle Vincent, Laurence Gérard, Vincent Calvez, Francois Clavel, Jean-Pierre Aboulker, Pierre-Marie Girard,

The aim of the present study was to assess the pharmacokinetic behavior of atazanavir-ritonavir when it is coadministered with tenofovir disoproxil fumarate (DF) in human immunodeficiency virus (HIV)-infected patients. Eleven patients enrolled in Agence Nationale de Recherche sur le SIDA (National Agency for AIDS Research, Paris, France) trial 107 were ... Read more >>

Antimicrob. Agents Chemother. (Antimicrobial agents and chemotherapy)
[2004, 48(6):2091-2096]

Cited: 131 times

View full text PDF listing >>



Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study.

Serge Diagbouga, Corine Chazallon, Michel D Kazatchkine, Philippe Van de Perre, André Inwoley, Souleymane M'Boup, Mireille Prince David, Aoua Thiéro Ténin, Robert Soudré, Jean-Pierre Aboulker, Laurence Weiss,

OBJECTIVE:To evaluate the feasibility and the relevance of the implementation of an alternative technique to flow cytometry (FC) for enumerating CD4 T cells (Dynabeads; Dynal Biotech, Oslo, Norway), based on quantifying CD4 T cells by epifluorescent microscopy following their isolation using anti-CD4 monoclonal antibody-coated magnetic beads. DESIGN:International multi-center study. Five ... Read more >>

AIDS (AIDS (London, England))
[2003, 17(15):2201-2208]

Cited: 41 times

View full text PDF listing >>





Advertisement

Disclaimer
0.8994 s